about
Protein Kinase D1 Signaling in Angiogenic Gene Expression and VEGF-Mediated AngiogenesisRegulation of T cell motility in vitro and in vivo by LPA and LPA2Biochemical and Structural Characterization of Lysophosphatidic Acid Binding by a Humanized Monoclonal AntibodyDevelopment of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.Engineering vascularized tissues using natural and synthetic small moleculesDiet-induced obesity links to ER positive breast cancer progression via LPA/PKD-1-CD36 signaling-mediated microvascular remodeling.A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo.Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapyExpression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathyLysophosphatidic acid in vascular development and diseaseLysophosphatidic acid suppresses endothelial cell CD36 expression and promotes angiogenesis via a PKD-1-dependent signaling pathway.Lysophosphatidic acid enhances stromal cell-directed angiogenesis.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Primary human endothelial cells secrete agents that reduce responsiveness to lysophosphatidic acid (LPA).Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming.Lysophosphatidic acid does not cause blood/lymphatic vessel plasticity in the rat mesentery culture modelRegression activity that is naturally present in vitreous becomes ineffective as patients develop proliferative diabetic retinopathyEvaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumorsLysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cells.Lysophosphatidic acid effects on atherosclerosis and thrombosis.High expression of the evolutionarily conserved alpha/beta hydrolase domain containing 6 (ABHD6) in Ewing tumors.The Role of Lysophosphatidic Acid on Airway Epithelial Cell Denudation in a Murine Heterotopic Tracheal Transplant ModelAlginate hydrogels of varied molecular weight distribution enable sustained release of sphingosine-1-phosphate and promote angiogenesis.Downregulation of Dicer expression by serum withdrawal sensitizes human endothelial cells to apoptosis.Immunohistochemical detection of autotaxin (ATX)/lysophospholipase D (lysoPLD) in submucosal invasive colorectal cancer.A metabolomics study of Qiliqiangxin in a rat model of heart failure: a reverse pharmacology approach.Expression of autotaxin and acylglycerol kinase in proliferative vitreoretinal epiretinal membranes.
P2860
Q26747243-9E13DA0D-EA22-404E-8DB1-E17B2BEC8DA5Q27320538-30AC1613-EA35-4BA0-A788-D47EB746380FQ27667249-D50BD1D0-0495-42CE-A92F-D20CDC4702F8Q30427967-9EE985F8-435B-4483-B0AA-4B332D895EB9Q30439954-14B9C6F5-6E34-44FB-81BA-E5D14C9F0765Q33618393-F0573BF7-44E9-402E-A20B-562D9ADD8FD9Q34208338-C74A71DC-B02A-4819-B77E-AFDF303871EBQ34292377-0430856D-6F8D-4377-A800-7CC4FBF4D034Q34518525-B8F5BF3C-0D09-4DA6-AE29-5DBA6DB0C6ADQ34941725-4C7BEA75-2C91-4070-9C9F-798FD54A8B05Q35018207-F6DF1A81-4F13-4A11-9BB2-90E40461E936Q35037444-8C009DDA-FA28-4DCF-AE12-830026E382CFQ35061469-66837986-DD0E-4CD7-BFE1-AC1F6D29B476Q35551835-03360FC1-9382-4C42-BF0C-449481959B40Q36083085-E7636AA8-8F0C-4A17-AF4E-A322019A951FQ36330107-BB2E70CA-C7CB-4B8D-B07E-AE82108CCEF0Q36940630-31E92139-08DE-4E0E-AD31-127872895B75Q37096381-DFECF244-ABB7-43A7-866C-A892E23E200CQ37098594-E8B85F6D-694D-483A-B654-BA453EDA15D7Q37372468-70E59C9D-A472-4ED5-AE71-42B403C22D12Q37486804-EF5DEB5C-8E5D-4D32-ACF0-B097E140284FQ39464516-77C3FD64-DDC1-49C6-A225-B1DFDE3D576AQ39608397-4EB59E2F-9C34-4309-8C0B-0D3CDA94AFE1Q39793314-699DEF70-509E-4670-8937-4A3CB1E2007BQ40584786-3DADAF0C-2E68-4965-947C-F435618F1804Q46131849-D34A569C-ECB6-4741-9A26-0B2DFFD28AFFQ46269102-78728539-D37B-44F3-AE7A-45B9CF5C20D2Q49133103-73AC4BA7-C029-464C-86DF-3FB158C47421Q50351086-8ABBC5BE-084F-44A2-919F-F03FDDE3AD03Q54548435-6BA36DC5-B577-45F4-95B5-8D53C76896D1
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lysophosphatidic acid (LPA) and angiogenesis.
@ast
Lysophosphatidic acid (LPA) and angiogenesis.
@en
type
label
Lysophosphatidic acid (LPA) and angiogenesis.
@ast
Lysophosphatidic acid (LPA) and angiogenesis.
@en
prefLabel
Lysophosphatidic acid (LPA) and angiogenesis.
@ast
Lysophosphatidic acid (LPA) and angiogenesis.
@en
P2093
P2860
P1433
P1476
Lysophosphatidic acid (LPA) and angiogenesis.
@en
P2093
Amy L Tucker
Carol M Rivera-Lopez
Kevin R Lynch
P2860
P2888
P304
P356
10.1007/S10456-008-9113-5
P577
2008-05-27T00:00:00Z